Psoriatic Arthritis

An observational study found patients with chronic inflammatory diseases who smoke may respond less to biologics than non-smokers.

Gerd Burmester, MD, discusses the favorable long-term safety data of upadacitinib treatment across rheumatic diseases.

A survey shows females with PsA have a greater disease burden than males with PsA.

If approved, zasocitinib could become a leading oral treatment for PsA.

A study found patients with psoriasis and psoriatic arthritis had a polyneuropathy relative risk of 22.09. However, an analysis revealed the neuropathy risk was not significant.

Discontinuation was less likely in the prospective Patient Support Program (PSP) group compared with the retrospective non-PSP group.

Diana Girnita, MD, PhD, highlights the crucial role of patient education, the integration of traditional and integrative medicine, and the importance of reliable information for improving health outcomes in chronic conditions.

More than half of patients with RA or PsA without obesity exhibited steatosis despite having low disease activity, with no differences observed based on methotrexate use and dosage.

Among all groups, fewer men with rheumatic disease were childless compared with controls.

Findings showed the rates of TEAEs were generally similar between upadacitinib 15 mg and active comparators in RA and PsA.

A national survey provides insight into the prevalence of arthritis based on race in the US from 2011 – 2018.

A study describes the structure and function differences of the Achilles tendon for PsA patients who self-report pain and those who don’t.

Data showed a significant reduction in pain for patients with psoriatic arthritis and inadequate response to TNF treated with guselkumab compared with placebo.

Treatment with guselkumab led to rapid, clinically meaningful improvements in disease activity among patients with severe psoriatic arthritis, which were maintained through 2 years.

Results revealed cDAPSA can help providers accurately measure the level of disease activity in patients and predict whether the patient will have radiographic progression.

Patients with psoriasis on biological agents might have a lower PsA risk than those on methotrexate, but patients on topical therapy have an even lower risk, a study found.

Among patients with PsA, men tend to present more peripheral joint movement, and women tend to exhibit more axial involvement, a new study found.

Adults with active PsA treated with guselkumab exhibited durable achievement of study endpoints associated with disease control, irrespective of baseline characteristics.

Patients in the active counseling group were more likely to achieve low disease activity or remission.

cfPWV values were significantly higher in patients with PsA compared with controls, even after adjusting for confounders.

The approvals were based on data from well-controlled studies of the drug in adult patients with PsA and RA.

In a new study, 16% of patients with RA and 22% with PsA had sleeping issues during the last week.

Benjamin J. Smith, DMSc, PA-C, discusses the importance of defining comorbidities in diagnosing PsA, as well as prescribing biologics.

After initiating treatment with ixekizumab, tender and swollen joint counts, pain, fatigue, and body surface area affected by psoriasis were significantly improved.

Combining algorithms SCORE2 and QRISK3 created the best predictive model to predict the cardiovascular risk for patients with PsA.